KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Palvella Therapeutics (PVLA) Leases (2019 - 2026)

Palvella Therapeutics has reported Leases over the past 4 years, most recently at $3.7 million for Q4 2022.

  • Quarterly Leases fell 5.22% to $3.7 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2022, down 5.22% year-over-year, with the annual reading at $3.7 million for FY2022, 5.22% down from the prior year.
  • Leases was $3.7 million for Q4 2022 at Palvella Therapeutics, up from $3.4 million in the prior quarter.
  • Over five years, Leases peaked at $4.0 million in Q3 2021 and troughed at $3.2 million in Q1 2020.
  • The 4-year median for Leases is $3.7 million (2022), against an average of $3.7 million.
  • Year-over-year, Leases grew 19.53% in 2021 and then decreased 14.47% in 2022.
  • A 4-year view of Leases shows it stood at $3.4 million in 2019, then grew by 14.49% to $3.9 million in 2020, then fell by 0.64% to $3.9 million in 2021, then fell by 5.22% to $3.7 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Leases are $3.7 million (Q4 2022), $3.4 million (Q3 2022), and $3.6 million (Q2 2022).